EP1124989A4 - Methode zur feststellung von krebs durch die bestimmung der expression von mage-10 - Google Patents

Methode zur feststellung von krebs durch die bestimmung der expression von mage-10

Info

Publication number
EP1124989A4
EP1124989A4 EP99954984A EP99954984A EP1124989A4 EP 1124989 A4 EP1124989 A4 EP 1124989A4 EP 99954984 A EP99954984 A EP 99954984A EP 99954984 A EP99954984 A EP 99954984A EP 1124989 A4 EP1124989 A4 EP 1124989A4
Authority
EP
European Patent Office
Prior art keywords
mage
expression
determining
detecting cancer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99954984A
Other languages
English (en)
French (fr)
Other versions
EP1124989A1 (de
Inventor
Thierry Boon-Falleur
Francis Brasseur
Donata Rimoldi
Etienne Deplaen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP1124989A1 publication Critical patent/EP1124989A1/de
Publication of EP1124989A4 publication Critical patent/EP1124989A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
EP99954984A 1998-10-30 1999-10-15 Methode zur feststellung von krebs durch die bestimmung der expression von mage-10 Withdrawn EP1124989A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/183,714 US6221593B1 (en) 1996-10-03 1998-10-30 Method for determining cancer by determining expression of MAGE-10
US183714 1998-10-30
PCT/US1999/024258 WO2000026407A1 (en) 1998-10-30 1999-10-15 Method for determining cancer by determining expression of mage-10

Publications (2)

Publication Number Publication Date
EP1124989A1 EP1124989A1 (de) 2001-08-22
EP1124989A4 true EP1124989A4 (de) 2002-09-04

Family

ID=22674021

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99954984A Withdrawn EP1124989A4 (de) 1998-10-30 1999-10-15 Methode zur feststellung von krebs durch die bestimmung der expression von mage-10

Country Status (4)

Country Link
US (1) US6221593B1 (de)
EP (1) EP1124989A4 (de)
AU (1) AU1119700A (de)
WO (1) WO2000026407A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210886B1 (en) * 1998-02-04 2001-04-03 Ludwig Institute For Cancer Research Method for diagnosing multiple myeloma by determining tumor rejection antigen precursors
ES2294346T3 (es) * 2002-11-28 2008-04-01 Peter Kufer Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage.
WO2012178087A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014463A1 (en) * 1996-10-03 1998-04-09 Ludwig Institute For Cancer Research MAGE-10 ENCODING cDNA, THE TUMOR REJECTION ANTIGEN PRECURSOR MAGE-10, ANTIBODIES SPECIFIC TO THE MOLECULE, AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
WO1994023874A1 (de) * 1993-04-14 1994-10-27 Zettl GmbH CNC Präzisions- und Sonderwerkzeuge Schneidwerkzeug
NZ282536A (en) * 1994-03-01 1998-07-28 Ludwig Inst Cancer Res Nucleic acid molecule useful as a primer in determining expression of a mage tumour rejections antigen precursor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014463A1 (en) * 1996-10-03 1998-04-09 Ludwig Institute For Cancer Research MAGE-10 ENCODING cDNA, THE TUMOR REJECTION ANTIGEN PRECURSOR MAGE-10, ANTIBODIES SPECIFIC TO THE MOLECULE, AND USES THEREOF

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] EMBL/GenBank/DDBJ databases; 8 September 1994 (1994-09-08), E. DE PLAEN, XP002202826, Database accession no. U10685 *
RIMOLDI DONATA ET AL: "cDNA and protein characterization of human MAGE-10.", INTERNATIONAL JOURNAL OF CANCER, vol. 82, no. 6, pages 901 - 907, XP000877098, ISSN: 0020-7136 *
S. LUCAS ET AL.: "Identification of human genes with tumor specific expression by representational difference analysis", 1996, XP002202767 *
See also references of WO0026407A1 *

Also Published As

Publication number Publication date
US6221593B1 (en) 2001-04-24
EP1124989A1 (de) 2001-08-22
AU1119700A (en) 2000-05-22
WO2000026407A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
EP1120976A4 (de) Verfahren zur bewegungsvektordetektion
EP1511995A4 (de) System und verfahren zur probendetektion auf der basis niederfrequenter spektralkomponenten
DE59700004D1 (de) Anordnung zur optischen Erfassung des Fahrbahnverlaufs
FR2784137B1 (fr) Procede permettant de corriger la caracteristique d'une sonde lambda lineaire
DE69914233D1 (de) Fahrzeug-Radargerät zum korrekten Entdecken von Gegenständen
BR9704486A (pt) Sistema de medição
DE69911279D1 (de) Hochgenaue Bildausrichtungsdetektion
FR2846503B1 (fr) Procede de determination des parametres optimaux d'une acquisition de radiographie
DE69916511D1 (de) Vorrichtung zum optischen Detektieren der Anwesenheit eines Gegenstandes
FR2805429B1 (fr) Procede de controle de la qualite numeriques distribuees par detection de faux contours
NO20004449D0 (no) FremgangsmÕte for Õ bestemme antibiotisk sensitivitet til bakterier
FR2791362B1 (fr) Procede de detection des bacteries sulfato-reductrices
FR2864145B1 (fr) Procede de detection de la presence d'un systeme de depollution par mesure de temperature
FR2839364B1 (fr) Procede de detection d'une reconnaissance molecukaire par electrochimiluminescence
FR2743633B1 (fr) Procede de detection des defauts d'une structure
FR2787199B1 (fr) Procede de detection, notamment de petites cibles marines
FR2667179B1 (fr) Procede de determination de l'orientation d'articles transportes.
DE69424234D1 (de) Vorrichtung zum Nachweis eines Analyten
EP1184463A4 (de) Methode zur messung von protein-protein wechselwirkungen
FR2778748B1 (fr) Procede de detection d'objets mobiles par sonar actif
FR2791669B1 (fr) Procede de preparation du fluoroformiate de tertiobutyle
FR2792417B1 (fr) Procede de determination de la permeabilite d'un materiau magnetique par perturbation d'une ligne coaxiale
EP1442296A4 (de) Biologisches assay-nachweisverfahren
FR2786880B1 (fr) Appareil de detection
EP0787183A4 (de) Methode zum "screenen" von unbekannten organismen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7G 01N 33/53 B, 7C 07H 21/00 B, 7C 07K 14/47 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020723

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20021202